BioNet, a leading biotechnology company, and BIA Separations, now part of Sartorius, has announced the successful development of an optimised mRNA manufacturing process.
BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimisation and upscale of a high-yield mRNA production process.
The new process has been applied successfully to the production of mRNA in the fight against COVID-19. The mRNA vaccine, produced at BioNet’s manufacturing facility, was developed by Chula Vaccine Research Center, Thailand (pictured), in collaboration with the University of Pennsylvania, USA.
Both BIA and BioNet are now collaborating on other projects, aiming to increase development capabilities and production capacity of nucleic acid vaccines in Europe, Australia, and low-middle income countries.